Rectify Pharmaceuticals Inc. has conducted preclinical testing on RTY-694, an oral dual-targeted positive functional modulator for use in the treatment of hepatobiliary disorders.
The collaboration aims to identify a small molecule that targets mutant androgen receptor (AR) mRNA splicing and causes selective destruction of the disease-causing mRNA.
The company analyzed genomic data provided by the Fred Hutch Cancer Center and compiled by the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) to identify mutational signatures and single nucleotide polymorphisms (SNPs) predictive of colorectal cancer.
AGEN-1721 was designed as an Fc-enhanced bifunctional antibody to selectively target FAP and neutralize TGF-β via an optimized TGF-βR2 TRAP moiety fused to an engineered Fc region, with the aim of maximizing effector functions.
Researchers from SL Bigen Inc. and collaborators presented the preclinical characterization of BM-205, a novel entity of engineered MSCs designed to exert antitumor functions.
By comparing the transcriptomic profile of tissue regeneration after induced damage in the small intestine and colon with their transcriptomic landscape in their steady state, researchers have identified a pathway that unlinks tissue regeneration from tumorigenesis.
Arovella Therapeutics Ltd. is heading toward the clinic with its lead product, ALA-101, which consists of a chimeric antigen receptor (CAR) targeting CD19 and invariant natural killer T (iNKT) cells.
Genesis Therapeutics Inc. has divulged phosphatidylinositol 3-kinase alpha (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
Matchpoint Therapeutics Inc. has synthesized new diazepino-thieno-quinoxaline compounds acting as MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
Nimbus Saturn Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety covalently linked to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety linked via a linker.
RSS
